SyntekaBio Inc (KQ:226330) — Market Cap & Net Worth
Market Cap & Net Worth: SyntekaBio Inc (226330)
SyntekaBio Inc (KQ:226330) has a market capitalization of $39.21 Million (₩57.86 Billion) as of May 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22754 globally and #1560 in its home market, demonstrating a -0.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SyntekaBio Inc's stock price ₩3170.00 by its total outstanding shares 18252618 (18.25 Million). Analyse 226330 cash flow metrics to see how efficiently the company converts income to cash.
SyntekaBio Inc Market Cap History: 2020 to 2026
SyntekaBio Inc's market capitalization history from 2020 to 2026. Data shows change from $284.50 Million to $39.21 Million (-21.20% CAGR).
Index Memberships
SyntekaBio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 0.01% | #792 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 0.01% | #792 of 1384 |
Weight: SyntekaBio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SyntekaBio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SyntekaBio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.54x
SyntekaBio Inc's market cap is 0.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $284.50 Million | $609.68 Million | -$6.49 Billion | 0.47x | N/A |
| 2021 | $221.41 Million | $316.66 Million | -$14.80 Billion | 0.70x | N/A |
| 2022 | $106.13 Million | $243.99 Million | -$4.51 Billion | 0.43x | N/A |
| 2023 | $176.14 Million | $123.41 Million | -$11.40 Billion | 1.43x | N/A |
| 2024 | $64.94 Million | $120.89 Million | -$7.21 Billion | 0.54x | N/A |
Competitor Companies of 226330 by Market Capitalization
Companies near SyntekaBio Inc in the global market cap rankings as of May 5, 2026.
Key companies related to SyntekaBio Inc by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #926 globally with a market cap of $28.21 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #2226 globally with a market cap of $10.06 Billion USD ( AU$14.22 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2339 globally with a market cap of $9.34 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2447 globally with a market cap of $8.82 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #926 | Veeva Systems Inc Class A | NYSE:VEEV | $28.21 Billion | $171.60 |
| #2226 | Pro Medicus Ltd | AU:PME | $10.06 Billion | AU$136.16 |
| #2339 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $9.34 Billion | $55.00 |
| #2447 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $8.82 Billion | $52.58 |
SyntekaBio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, SyntekaBio Inc's market cap moved from $284.50 Million to $ 39.21 Million, with a yearly change of -21.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩39.21 Million | -18.61% |
| 2025 | ₩48.18 Million | -25.81% |
| 2024 | ₩64.94 Million | -63.13% |
| 2023 | ₩176.14 Million | +65.97% |
| 2022 | ₩106.13 Million | -52.07% |
| 2021 | ₩221.41 Million | -22.17% |
| 2020 | ₩284.50 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of SyntekaBio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.21 Million USD |
| MoneyControl | $39.21 Million USD |
| MarketWatch | $39.21 Million USD |
| marketcap.company | $39.21 Million USD |
| Reuters | $39.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more